Outset Medical (OM) Earnings Date & Reports

Key Takeaways

• Total revenue rose about 14% year over year to $33.6 million, with product revenue up 15% to $23.7 million.
• Recurring revenue (consumables plus service) increased 10% to $23.1 million, underscoring a stable, predictable base.
• Non-GAAP gross margin reached 40.8%, up roughly 100 basis points from the prior-year period.
• Non-GAAP net loss was $12.9 million, compared with $12.4 million in the same quarter last year.
• Management reiterated full-year 2026 revenue guidance of $125 million to $130 million.
• The company ended the quarter with $140.7 million in cash, equivalents, short-term investments, and restricted cash.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Explore Trending AI Robots to see AI-driven trading strategies currently capturing market attention.

Earnings Context and Why It Matters

Outset Medical's quarterly results are a key checkpoint for investors tracking the company's path toward profitability. The maker of the Tablo Hemodialysis System has spent recent years widening gross margins, cutting cash burn, and narrowing losses, even as quarterly revenue has been uneven due to the timing of large capital purchases. This report matters because it shows whether revenue growth is reaccelerating while margins keep improving, a combination management has framed as essential to reaching its next milestone of a 50% company-wide gross margin. Against a backdrop of hospitals increasingly "insourcing" dialysis, the quarter offers a read on demand for Tablo consoles and recurring consumables.

Reported Results

For the third quarter ended September 30, 2026, Outset Medical reported total revenue of $33.6 million, up approximately 14% compared with the prior-year period. Product revenue grew 15% to $23.7 million, led by console revenue of $10.5 million (up 26%) and consumable revenue of $13.2 million (up 8%). Service and other revenue increased 12% to $9.9 million, while recurring revenue rose 10% to $23.1 million.

Non-GAAP gross margin was 40.8%, up roughly 100 basis points year over year, driven by product cost improvements, reduced overhead, and service efficiencies. Product gross margin was 44.2%, while service and other gross margin climbed 760 basis points to 32.4%. Non-GAAP operating expenses were $24.2 million, and non-GAAP net loss was $12.9 million, compared with $12.4 million a year earlier. GAAP (Generally Accepted Accounting Principles) net loss narrowed to about $14.7 million from $17.8 million.

The company reiterated its 2026 revenue outlook of $125 million to $130 million and full-year non-GAAP gross margin in the low-40% to mid-40% range.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are researching a single ticker like OM or surveying an entire sector, the AI Screener offers a structured way to surface actionable ideas.

Market Reaction and Investor Sentiment

Investor sentiment heading into the print reflected a company still working toward sustained profitability after a sharp decline in its share price over the past year. The third-quarter results showed revenue growth reaccelerating to about 14% and a non-GAAP gross margin above 40%, reinforcing the margin-expansion narrative management has emphasized. Meanwhile, the reiterated full-year guidance signaled stability in the outlook. Because Outset Medical remains a growth-stage medical technology company with a history of capital-order timing swings, the market's read on the quarter is likely to hinge on whether improving margins and disciplined spending can translate into a narrower path to profitability rather than on any single revenue figure.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching several drivers tied to Outset Medical's console growth strategy. Management has outlined three priorities: a refresh opportunity spanning more than 3,000 consoles and an estimated $150 million revenue opportunity over the coming years, expansion within existing customer sites, and new customer acquisition across unpenetrated hospitals.

Margin progression remains a central theme. The company continues to target a 50% company-wide gross margin, and the mix between lower-margin console sales and higher-margin consumables and service revenue will influence how quickly that goal is approached. A heavier console mix could pressure gross margin toward the lower end of guidance.

Cash management is another area to monitor. The company used $10.3 million in cash during the quarter and expects roughly $40 million for the full year, supported by expense discipline and working capital management. With $140.7 million in cash and equivalents at quarter-end, the balance sheet remains a focal point as the company works toward cash-flow breakeven. Finally, the broader environment for insourced dialysis, hospital capital spending patterns, and the commercial pipeline's conversion rate will all shape the trajectory into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations